Search

Your search keyword '"Triebel, Frederic"' showing total 7 results
Start Over Author "Triebel, Frederic" Journal journal for immunotherapy of cancer
7 results on '"Triebel, Frederic"'

1. 359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

Author

Pousa, Antonio López, primary, Felip, Enriqueta, additional, Forster, Martin, additional, Doger, Bernard, additional, Roxburgh, Patricia, additional, Bajaj, Pawan, additional, Peguero, Julio, additional, Carcereny, Enric, additional, Krebs, Matthew, additional, Mueller, Christian, additional, and Triebel, Frederic, additional

Published
2021
Full Text
View/download PDF

2. 948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

Author

Wildiers, Hans, primary, Dirix, Luc, additional, Armstrong, Anne, additional, Cuypere, Eveline De, additional, Dalenc, Florence, additional, Chan, Steven, additional, Marme, Frederik, additional, Schröder, Carolina Pia, additional, Huober, Jens, additional, Vuylsteke, Peter, additional, Jacquin, Jean-Philippe, additional, Brain, Etienne, additional, Kümmel, Sherko, additional, Pápai, Zsuzsanna, additional, Mueller, Christian, additional, Brignone, Chrystelle, additional, and Triebel, Frederic, additional

Published
2021
Full Text
View/download PDF

5. New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Author

Adusumilli, Prasad S., primary, Cha, Edward, additional, Cornfeld, Mark, additional, Davis, Thomas, additional, Diab, Adi, additional, Dubensky, Thomas W., additional, Evans, Elizabeth, additional, Grogan, Jane L., additional, Irving, Bryan A., additional, Leidner, Rom S., additional, Olwill, Shane A., additional, Soon-Shiong, Patrick, additional, Triebel, Frederic, additional, Tuck, David, additional, Bot, Adrian, additional, Dansey, Roger D., additional, Drake, Charles G., additional, Freeman, Gordon J., additional, Ibrahim, Ramy, additional, Patel, Salil, additional, and Chen, Daniel S., additional

Published
2017
Full Text
View/download PDF

6. New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31st Annual Meeting of the Society for Immunotherapy of Cancer, 2016.

Author

Adusumilli, Prasad S., Cha, Edward, Cornfeld, Mark, Davis, Thomas, Diab, Adi, Dubensky Jr., Thomas W., Evans, Elizabeth, Grogan, Jane L., Irving, Bryan A., Leidner, Rom S., Olwill, Shane A., Soon-Shiong, Patrick, Triebel, Frederic, Tuck, David, Bot, Adrian, Dansey, Roger D., Drake, Charles G., Freeman, Gordon J., Ibrahim, Ramy, and Patel, Salil

Subjects
IMMUNOTHERAPY, CANCER treatment, DRUG development, CONFERENCES & conventions
Abstract

This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

7. New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31 st Annual Meeting of the Society for Immunotherapy of Cancer, 2016.

Author

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, and Chen DS

Subjects
Cancer Vaccines immunology, Humans, Neoplasms immunology, Tumor Microenvironment drug effects, Cancer Vaccines therapeutic use, Immunotherapy, Neoplasms drug therapy, Tumor Microenvironment immunology
Abstract

This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results